SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The crypto $SLAP is trending due to community enthusiasm and its increasing visibility. Community members highlight the project's active team, real-world partnerships, and the meme-ability of the name itself. Many express a bullish sentiment, encouraging others to 'DCA and HODL' and to 'slap the bears.'

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION is trending amid community excitement and speculation, potentially fueled by prominent figures' involvement. Discussions revolve around possible short squeezes, long-term potential, and comparisons to competitors in the DEX space, like Hyperliquid. Bullish sentiment is strong, with many viewing it as a promising project within the broader crypto ecosystem.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer is trending as the community discusses its potential, particularly around integrations and on-chain development capabilities. Bullish sentiment centers on the project's technology, with some suggesting it's undervalued, while bears cite concerns about price action and tokenomics. Recent upgrades and developer activity are also being closely watched for their impact on adoption.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to community outrage after an FDA official made negative comments about the company's drug, Lupkynis, on social media, causing a significant stock drop; despite the retraction, the stock is struggling to recover. The community is calling for accountability and discussing potential motivations, as well as broader concerns about the FDA's integrity. Some are still optimistic, anticipating positive news from upcoming earnings and Aur200 developments.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is gaining attention as its community, the Wolfpack, rallies around the token and hints at upcoming news. With a strong emphasis on community support and long-term holding, many believe $SAILANA has the potential for significant growth. Discussions frequently reference a potential 1000x increase and draw comparisons to the early days of Shiba Inu.

MUSE

$MUSE is trending due to community excitement around its potential as a low market cap altcoin, with discussions focusing on historical price pumps in November and the possibility of breaking its all-time high. Traders are actively watching level 2 data, noting volatility and potential for significant swings given its limited token circulation. The community is also discussing its role in the NFT20 ecosystem and potential for high rewards.

Meet Mochi, the cutest IP on Base – Named after Coinbase CEO Brian Armstrong’s pet cat! Launched before Base’s main-net launch in August 2023, Mochi is a first mover on Base, and is committed to help Base and Coinbase is their mission to bring the next billion users onchain.   Mochi has already received a grant from Coinbase for its efforts to onboard new users and continues to release news and developments that see recognition from Coinbase and Base team members and the wider Base community.   Designed by the artist behind Pudgy Penguins, Antoine Mingo - Mochi’s IP has accrued billions of GIF views globally and gained a large non-crypto native following on social media platforms such as Instagram. Mochi’s mission is to become the most retail friendly IP on Base and position itself for the millions of retail investors being onboarded to Base in 2025 through Coinbase and Base’s efforts.   Join Mochi and the vibrant Mochi community in achieving this mission through weekly initiatives and many exciting developments yet to come and be a part of Base’s journey to becoming the largest onchain economy in crypto!

Mochi

MOCHI CRYPTO is trending as a potential beneficiary of the BASE chain narrative, drawing comparisons to TOSHI and other meme coins on the Coinbase ecosystem. Community members highlight the project's locked liquidity, Coinbase grant, and utility, positioning it as an undervalued opportunity with significant upside potential. Some users are also excited about a potential exchange listing.

Colgate-Palmolive Co. engages in the manufacturing and distribution of consumer products. It operates through the Oral, Personal, and Home Care, and Pet Nutrition segments. The Oral, Personal, and Home Care segment includes toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other similar items. The Pet Nutrition segment offers specialty pet nutrition products manufactured and marketed by Hill’s Pet Nutrition. The company was founded by William Colgate in 1806 and is headquartered in New York, NY.

Colgate-Palmolive Co.

Colgate-Palmolive is trending as community members assess whether the recent rally is justified despite softer volumes and missed sales expectations, even with a recent earnings beat. Discussions include the impact of pricing strength and currency benefits on sales growth, as well as debates over technical analysis and future outlook for the stock. Some traders are eyeing potential upside based on oversold conditions and call options, while others express concerns about valuation and declining profits.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

TVTX is trending due to positive revenue growth driven by its kidney disease treatment, Filspari, and optimism surrounding potential FDA approval for expanded use. Community members are discussing the stock's potential for further gains, citing a large short interest which could fuel a squeeze. Analysts have also weighed in with price target increases based on the company's recent earnings report.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending as discussions revolve around its strategic partnership with Tempus AI, particularly the expansion into colorectal cancer testing. The community is also focused on potential catalysts like reimbursement approvals and strong clinical data from recent presentations. Some are speculating on the company's valuation and potential for a buyout, while others are analyzing technical indicators for potential breakouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow 

Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo (Lenacapavir)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo (lenacapavir), the companys...

Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Gilead (GILD) delivered earnings and revenue surprises of +14.88% and +4.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences Announces Third Quarter 2025 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing...

Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?

Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit

Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit As noted earlier, investors face a monumentally important and extremely busy week ahead that includes rates...

Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$118.89
Prev Close	$118.44
Open	$116.06
Dividend Yield	3.33%
50-Day Moving Average	$115.69
Beta	0.36
Avg. Volume	7.21M
PE Ratio	23.83

52-Week High	$124.61
52-Week Low	$86.08
Market Capitalization	$148.64B
EPS (Annual)	$0.3825
Price to Book	7.56
Revenue Per Employee	$1.63M
Enterprise Value/EBITDA	N/A

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GILD News

GILDGilead Sciences, Inc.